Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.

@article{Pommier2004CamptothecinsAT,
  title={Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.},
  author={Yves Pommier},
  journal={Current medicinal chemistry. Anti-cancer agents},
  year={2004},
  volume={4 5},
  pages={
          429-34
        }
}
  • Y. Pommier
  • Published 31 August 2004
  • Biology, Medicine
  • Current medicinal chemistry. Anti-cancer agents
Camptothecins selectively target topoisomerase I (Top1) by trapping the catalytic intermediate of the Top1-DNA reaction, the cleavage complex. Hence, camptothecins represent a paradigm for targeting macromolecular interactions. Instead of preventing the binding of the two macromolecules they target (Top1 and DNA), camptothecins slow down the dissociation of these macromolecules. The activity of camptothecins underlines the usefulness of screening for drugs that inhibit the dissociation of… Expand
Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides
TLDR
Human topoisomerase II is the cellular target for a number of widely used antitumor agents, such as etoposide (VP16), and the use of triple-helical DNA structures offers an efficient strategy for targeting topo II-mediated cleavage to DNA specific sequences. Expand
Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
TLDR
Agents that inhibit tyrosyl-DNA phosphodiesterases 1 and 2 have many applications in biochemical and physiological research and they have the potential to become anticancer and antiviral drugs. Expand
Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine
TLDR
It appears that sub-apoptotic concentrations of sanguinarine can suppress breast cancer cell proliferation for extended lengths of time, and that this effect results from a relatively brief period of activity when the drug is concentrated in the nucleus. Expand
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
TLDR
The use of γ-H2AX as a pharmacodynamic biomarker for the clinical development of the indenoisoquinolines is discussed, which results in the rapid and sustained phosphorylation of histone H2AX. Expand
Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.
TLDR
Investigation of prostate cancer cells induced by drugs like camptothecin, staurosporine, and etoposide shows that betulinic acid inhibits formation of apoptotic topoisomerase I-DNA complexes and prevents the cellular topoisomersase I from directly participating in the apoptotic process. Expand
DNA Topoisomerases of Leishmania parasites; druggable targets for drug discovery.
TLDR
Several facts about Top and Top inhibitors as potential antileishmanial drugs, which may represent a promising strategy for the control of this disease of public health importance are highlighted. Expand
Simple and Fast DNA Based Sensor System for Screening of Small-Molecule Compounds Targeting Eukaryotic Topoisomerase 1
TLDR
A novel DNA-based assay that allows for screening of the effect of small-molecule compounds targeting the binding/cleavage or the ligation steps of topoisomerase 1 catalysis and can be performed in non-specialized laboratories. Expand
Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.
  • V. A. Rao
  • Biology, Medicine
  • Antioxidants & redox signaling
  • 2013
TLDR
The growing list of agents that appear to chelate iron and inhibit topoisomerases prompts the question of whether and how these two distinct mechanisms might interplay for a cytotoxic chemotherapeutic outcome. Expand
Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
TLDR
Evidence is provided that the Schizosaccharomyces pombe Rad32(Mre11) nuclease activity is involved in the removal of both Top2 from 5' DNA ends as well as Top1 from 3' ends in vivo, and analysis of separation of function mutants suggests that MRN-dependent topoisomerase removal contributes significantly to resistance against topoisomersase-trapping drugs. Expand
Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition
TLDR
It is demonstrated that Rad18 E3 ligase activity is essential for appropriate FA pathway activation and DNA damage tolerance after CPT treatment, and defined a novel pathway of Rad18-dependent DSB repair that is dissociable from known Rad 18-mediated DNA repair mechanisms based on its independence from PCNA ubiquitination and requirement for E3ligase activity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A
抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。
Bioorg Med Chem
  • Bioorg Med Chem
  • 2004
Curr Pharm Design
  • Curr Pharm Design
  • 2004
Mol Cancer Ther
  • Mol Cancer Ther
  • 2004
Bioorg Med Chem Lett
  • Bioorg Med Chem Lett
  • 2003
Cancer Res
  • Cancer Res
  • 2003
Crit Rev Oncol Hematol
  • Crit Rev Oncol Hematol
  • 2003
Curr Topics Med Chem
  • Curr Topics Med Chem
  • 2003
Mutat Res
  • Mutat Res
  • 2003
Adv Cancer Res
  • Adv Cancer Res
  • 2001
...
1
2
3
...